RecruitingNCT06777628

Immunophenotype of PBMC to Early Predict Response to Immunotherapy in Hepatocellular Carcinoma

Immunophenotype of Peripheral Blood Mononuclear Cells to Early Predict Response to Immunotherapy in Hepatocellular Carcinoma

Sponsor

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Enrollment

100 participants

Start Date

Sep 15, 2024

Study Type

OBSERVATIONAL

Conditions

Liver Cancer, Adult

Summary

The study is aimed to test the performance of a simple, easy, reproducible cytofluorimetric assay to complement imaging studies for: * predicting response to immune-therapeutic regimens in HCC in the early phase of treatment, * to rule out pseudo-progression, * to early predict the escape from effectiveness of treatment.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is analyzing immune cells in the blood of patients with liver cancer (hepatocellular carcinoma) who are receiving immunotherapy, to see whether specific patterns of immune cells can predict early on whether the treatment will work. The goal is to help doctors personalize treatment decisions based on a patient's immune profile. **You may be eligible if...** - You are 18 years of age or older - You have been diagnosed with liver cancer (hepatocellular carcinoma) - You are receiving treatment and follow-up at the participating center - You are willing to provide written informed consent **You may NOT be eligible if...** - You have other immune-related diseases - You have an HIV infection Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.